A clean laser focused Company
The simplest but most relevant analysis you will find on the Company. Read slowly, think carefully & you might agree !.... Do comment at the end for any clarification/ views.
Information last updated - June 29, 2020
Summary
Decent long term compounding story.
Sector Interest
😘 Flavor of the season.
Financials
🙂 Decent business growth, stable margins, ok cash generation. Low debt.
Technicals
🙂 Long term chart broken out in Jan 20 and retested the breakout in Mar and May 20
Management
🙂 Good promoter driven Company with a solid professional board.
Valuation
🙂 Closer to the lower end of historical valuation band.
Investor Interest
🙂 Decent. Institutions have been accumulating from public.
SWOT
Strengths
- Amongst top ten pharma companies in India
- Leadership position in anti infectives segment
- Able management with strong professional board
- Low net debt levels
- Consistent business growth and stable margins
Weaknesses
- Significant (40%) business is from overseas
- Cash flow from operations are volatile vis-a-vis business growth and margins
- Valuations are not overly attractive
Threats
- Disruptions caused due to Covid2019. Surgeries are postponed impacting Company's anti infectives
- Regulatory approvals
Opportunities
- Improving performance in the chronic therapy segments like Neuro / CNS, Derma and Anti-Diabetes
- Significantly growing Vitamins/ Minerals / Nutrients segment. This segment shall continue to find more and more acceptance in the post Covid2019 world
- As on March 31, 2020, the Company has filed a total of 144 ANDAs (including 2 NDA) with the US FDA and has received 89 approvals (including 13 tentative approvals and 2NDAs)
Management Quality
- Alkem is currently run by Sandeep Singh (MD). He is from the promoter family and is associated with the Company since 2003.
- Based on my reading so far, he seems reasonable and well regarded.
- The pedigree of people on the Board further testifies towards the corporate governance standards at the Company.
Financials
Auditors - B S R & Co. LLP
Bankers - Citi, HDFC, HSBC, Kotak Mahindra, SBI & others
Credit Rating - Crisil (AA+ Stable, A1+), Fitch - IND A1+
- Company has a strong credit rating
- Revenues have grown consistently though with higher base the rate of growth is slowing down
- Margins are stable and return on capital is good
- Cash flow from operations have got hit in the current year but that maybe because of COVID2019 impact. I will be watching this very closely.
- Debt levels are comfortable
- Valuations are neither too low nor too high. From current levels, upside potential is more than significant downside risk. (Note: March 20 valuations are calculated at Rs 2,282/ share. Accordingly, please adjust the same as per current market price)
Important Links
Old Analysis
Other Important Observations​
– NA
Long Term Chart - a key parameter to understand the true nature of any Company
- Company seems to be a decent performer and currently retesting it’s previous breakout levels.
Interactive Chart & Current Technicals
List of All Analyzed Companies
Companies
Pharmaceutical generics, formulations and neutraceutricals
Rebooting the energies
You can love it, you can hate it but you cannot ignore it !
Hope that it keeps plugging in
Keeps your spirit high !
inves4 Model Portfolio
An actively managed portfolio - cross between fundamental and technical analysis
- select companies - controlled risk - regular profit booking
Click for details
Relevant News/ Insights​
Pharma, FMCG push hiring activity in India by 24% in September: Naukri.com
Driven by industries like pharma, fast-moving consumer goods, education and IT, hiring activity in India saw a growth of 24…
Blackstone, Partners Group Holding in race to acquire Piramal Glass
The investment firms have progressed to the final round of bidding for India’s Piramal Glass, the people said, asking not…
First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health's Guardant360® CDx, gains credibility among oncologists in Asia, Middle East...
The U.S. Food and Drug Administration (FDA) has approved Guardant Health’s liquid biopsy, Guardant360® CDx, for tumor mutation profiling in…
Stocks: When to sell? - Part 1
The most difficult and confusing topic in stock investing !
COVID2019 and stock investing – Part 4 – is it a blessing in disguise for the Indian economy !
At first read, the presented arguments may sound counter intuitive. However, think carefully and you might agree.
Is it time to buy the Indian midcaps – Update December 31, 2019
4th note in the series... the last one for calendar year 2019 !
Disclaimer: The information presented above is no advice/ recommendation. Please do your own independent research before taking any investment related decision.
Good and simple
Thanks Kavinder.
Easy to understand .
Thanks 🙂
Congrats to Inves4 for completing a year and wishing a long and successful journey ahead.
Really liked the lucid company review (Alkem) that you have posted.
The Summary, SWOT, analysis of Long term charts etc were quite useful in getting a comprehensive view of the Co.
Thanks Kartik. Glad that you liked and found it useful. Look forward to continue offering simplistic analysis 🙂